Document |
Document Title |
WO/2023/017451A1 |
The present invention relates to compounds of formula (I). The compounds maybe used to antagonise the Stimulator of Interferon Genes (STING) protein and may thereby treat liver fibrosis, fatty liver disease, non-alcoholic steatohepatitis...
|
WO/2023/011573A1 |
The present invention relates to an aromatic acetylene derivative, a preparation method therefor, and a medical use of a pharmaceutical composition containing the derivative. Specifically, the present invention relates to an aromatic ace...
|
WO/2023/015184A1 |
Provided herein is a process for the preparation of (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden
-1-yl)-1-methyl-1H-pyrazole-4-carboxamide, intermediates thereof, and salts of the foregoing.
|
WO/2023/015138A1 |
The present disclosure relates to strapped calixpyrrole compounds, polymer monomers and polymers comprising strapped calixpyrrole substructures, and compositions thereof. Also provided herein are methods of use of said strapped calixpyrr...
|
WO/2023/012044A1 |
A compound of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, which can be used as fungicides.
|
WO/2023/014611A1 |
Pyrimidine compounds of formula (I) shown herein. Also disclosed are pharmaceutical compositions containing one of the pyrimidine compounds and methods of using the pyrimidine compounds to treat or prevent chemotherapy- induced periphera...
|
WO/2023/011574A1 |
Disclosed in the present invention are an aromatic acetylene derivative, a preparation method therefor, a pharmaceutical composition containing the derivative, and the use of the aromatic acetylene derivative or the pharmaceutical compos...
|
WO/2023/012821A1 |
The present invention provides a process for the preparation of a compound of Formula I, wherein, # indicates the attachment to isoxazoline ring and * indicates the attachment to the carbonyl carbon, The present invention particularly pr...
|
WO/2023/011610A1 |
Provided are a benzodioxane compound, a preparation method therefor and an application thereof. Specifically, the present invention relates to a compound having EGFR inhibitory activity, a pharmaceutically acceptable salt or pharmaceutic...
|
WO/2023/009503A1 |
Provided herein are photoactive fluorescent 2-diazo-3-oxo-2,3-dihydrospiro[indene-l,9'-xanthene] derivatives and other similar compounds of formula (I) for use in labeling proteins, for example, tagged proteins, and for use in visualizin...
|
WO/2023/009585A2 |
Provided herein are compounds having activity against TTR related conditions, and pharmaceutically accepted salts and solvates thereof. Also provided are methods of using the compounds for inhibiting and preventing TTR aggregation and/or...
|
WO/2023/008577A1 |
The present invention addresses the problem of providing a Ras/Raf binding inhibitor compound that has the effect of inhibiting Ras/Raf signaling in drug-resistant cancer cells and in a wide range of Ras mutant cancers. A Ras/Raf binding...
|
WO/2023/009475A1 |
The present disclosure provides compounds of Formula (I) and (II), which may be R0CK2 inhibitors. The present disclosure also provides pharmaceutical compositions and kits comprising the compounds, and methods of treating or preventing d...
|
WO/2023/006019A1 |
Disclosed in the present invention are a polysubstituted benzene PD-L1 inhibitor, a composition and the use thereof. The compound has a structure as represented by general formula (I). The inventor of the present invention confirmed by m...
|
WO/2023/003234A1 |
The present invention provides: a novel compound capable of improving the luminous efficiency, stability and lifespan of an element; an organic electric element using same; and an electronic device thereof.
|
WO/2023/001298A1 |
The present invention relates to a method for preparing a hepatitis B virus nucleocapsid inhibitor. Specifically, the method of the present invention obtains a novel method for preparing a compound represented by formula (I) (each group ...
|
WO/2023/001818A1 |
The invention relates to a compound having one of the following ionic chemical structures (I), "R" represents an "alkyl" or "O-alkyl" group optionally comprising one or more unsaturations, as a linear or branched chain, of 1 to 30 carbon...
|
WO/2023/002443A1 |
The disclosure provides compounds of Formula (I): (I) as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certai...
|
WO/2023/001299A1 |
The present invention relates to a crystal form of a compounds represented by formula (I), and preparation therefor and an application thereof. Specifically, also disclosed in the present invention are a variety of crystal forms of the c...
|
WO/2023/002165A1 |
P324681WO 319 ABSTRACT INHIBITOR COMPOUNDS The present invention relates to compounds of Formula (I) that target the MLH1 or MLH1 and PMS2 proteins that are components of the DNA Mismatch Repair (MMR) process: Formula (I) wherein R6, Y1,...
|
WO/2023/003973A1 |
Disclosed herein are inhibitors of deubiquitinating (DUB) enzyme USP7 (Ubiquitin Specific Protease 7). Also provided are methods of treating a disease or disorder modulated by USP7.
|
WO/2023/001237A1 |
Disclosed are compounds of formula I or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods related to agonists of glucagon-like peptide-1 receptor (GLP-1R). In particular, the compounds and compos...
|
WO/2023/001028A1 |
A heteroaryl-3-piperidinedione compound and the use thereof. Particularly disclosed are a compound represented by formula (II) and a pharmaceutically acceptable salt thereof.
|
WO/2023/001794A1 |
There are disclosed certain substituted pyrazine-2-carboxamides of Formula (I), and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are inhibitors of hematopoi...
|
WO/2023/288253A1 |
Provided herein are compounds of Formula (I), their pharmaceutically acceptable salts, and their pharmaceutical compositions: (I) wherein R1, R2, R3, L, X, and Ar are defined in the present disclosure. The compounds are inhibitors of cyc...
|
WO/2023/285497A1 |
The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein X, D, R1 to R4, and R6 to R10 are as described herein. Further provided are pharmaceutical composi...
|
WO/2023/284782A1 |
A method for screening a compound used for treating or preventing mHTT-related neurodegenerative diseases, target protein used for screening, and a corresponding compound.
|
WO/2023/287704A1 |
Provided herein are compounds that bind to BF3 of an androgen receptor (AR), which can modulate the AR for the treatment of Kennedy's disease and for the treatment of cancer.
|
WO/2023/286855A1 |
The purpose of the present invention is to provide an excellent agricultural or horticultural plant disease control agent. Provided are: a formamide derivative represented by general formula [I] and the like (in the formula, X1, X2, X3...
|
WO/2021/245083A9 |
The present disclosure relates to heterocyclyl pyridine compounds, processes and intermediates for their preparation as well as the uses thereof for controlling phytopathogenic microorganisms, such as phytopathogenic fungi.
|
WO/2023/284869A1 |
Provided are a sulfur/phosphorus-containing aryl compound and an application thereof, and specifically disclosed are a compound represented by formula (V) and a pharmaceutically acceptable salt thereof.
|
WO/2023/284022A1 |
Provided are a phenanthroimidazole derivative, and a preparation method therefor and an application thereof. The phenanthroimidazole derivative has a structural formula as shown in formula (I), R being an electron donor group, wherein by...
|
WO/2023/283256A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
WO/2023/283453A1 |
The disclosure herein provides phenyl acetamide based compounds of Formula (I), (I-a), (II), and pharmaceutical compositions thereof, for the modulation of IL-17A, useful in the treatment of inflammatory conditions such as psoriasis.
|
WO/2023/282676A1 |
The present specification relates to a compound and an organic light-emitting element comprising same.
|
WO/2023/283428A1 |
Disclosed are compounds l-A and I -B and salts thereof that bind to and modulate cereblon activity. In some embodiments, the binding and modulation of cereblon results in the degradation of IKAROS family zinc finger proteins (e.g., IKZF2).
|
WO/2023/283523A1 |
The present disclosure generally relates to 2,3-dihydrobenzo[b][1,4]dioxin-6-yl containing compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclos...
|
WO/2023/280182A1 |
Provided in the present invention is a compound serving as a KAT6 inhibitor. Specifically, provided in the present invention is a compound having a structure as represented by the following formula (I) and formula (XIV), or an optical is...
|
WO/2023/281271A1 |
There is provided pharmaceutical compounds of formula I, wherein R1, R2, R3, R4, R5, R6, Y1, Y2, Y3, X and Z have meanings given in the description, which compounds are useful in the treatment of autoimmune and/or fibrotic diseases, incl...
|
WO/2023/279986A1 |
A compound of formula I and a use thereof as an MALT1 inhibitor, and a pharmaceutical composition containing the compound. The compound can be used to treat diseases or disorders such as cancer.
|
WO/2023/279280A1 |
Disclosed in the present invention are an inhibitor of 1-methyl-7-chloro-4-((methoxyaryl heteroyl)amino)-N-(arylsulfonyl)-indole-2-carboxamide FBPase having a novel structure, a preparation method therefor, and a pharmaceutical compositi...
|
WO/2023/280290A1 |
The present invention relates to a class of pyrrole sulfonyl derivatives, a preparation method therefor, a pharmaceutical composition containing same, and the use thereof in the preparation of a drug. Specifically, the present invention ...
|
WO/2023/274396A1 |
A class of benzazepine heterocyclic compounds that can be used as RORγt agonists and an application thereof in medicine, as well as a pharmaceutical composition comprising this class of compound and an application thereof in medicine. S...
|
WO/2023/278600A1 |
The disclosure relates to compounds that act as inhibitors of KRAS; pharmaceutical compositions comprising the compounds; and methods of treating or preventing disorders, including cancer and other proliferation diseases.
|
WO/2023/275744A1 |
The present disclosure relates to 3-substituted-5-(1-(quinolin-2-yl)piperidin-4-yl)-1,2,4-oxad
iazole derivatives for use in the treatment and/or prevention of tuberculosis. Formula (I)
|
WO/2023/275337A1 |
The invention relates to the compound of general formula (I) as novel inhibitors of transglutaminases, to methods for producing the inventive compounds, to pharmaceutical compositions containing said inventive compounds and to their use ...
|
WO/2023/274251A1 |
The present invention relates to a polycyclic compound for inhibiting RNA helicase DHX33, and an application of the compound. In particular, the present invention relates to a compound as represented by formula I or a pharmaceutically ac...
|
WO/2023/274040A1 |
Provided are a crystal form of a triazolopyridine-substituted indazole compound and a preparation method therefor; and specifically disclosed are a crystal form of a compound as represented by formula (I) and a preparation method therefor.
|
WO/2023/277014A1 |
The present invention provides: a compound that has an excellent controlling effect against harmful arthropods, and that is represented by formula (I) [where Z1 and Z2 each represent an oxygen atom or the like, G1 represents CR1a or the ...
|
WO/2023/274257A1 |
An imidazole compound as shown in formula I or a pharmaceutically acceptable salt and an intermediate thereof. The imidazole compound as shown in formula I can significantly inhibit AA-induced platelet aggregation, improves MCAO/R-induce...
|